Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lexicon Pharmaceuticals has completed a Phase IIa clinical trial of LX6171 in a study designed to explore the potential effects of the drug candidate in subjects with age-associated memory impairment. Although the compound was well tolerated, there was no clear demonstration of activity for the various cognitive domains evaluated.
Subscribe to our email newsletter
In the recently-completed Phase IIa clinical trial, daily doses of LX6171 or placebo were given to 121 healthy elderly subjects with age-associated memory impairment. The study evaluated safety, tolerability, and cognitive effects of LX6171 over four weeks.
Although LX6171 was well tolerated at all doses evaluated, the trial did not result in significant effects on parameters of attention or memory that would justify further studies in therapeutic indications prioritized by the company.
Lexicon will concentrate its ongoing clinical development efforts on four drug candidates: two drug candidates that are currently in Phase II development for irritable bowel syndrome and carcinoid syndrome, LX1031 and LX1032, as well as two drug candidates for rheumatoid arthritis and diabetes that are currently in early-stage clinical development.
Arthur Sands, president and CEO of Lexicon, said: Although we are disappointed with the clinical trial results for LX6171, our portfolio strategy enables us to focus our resources on those programs that are seen to have the greatest opportunity for ultimate success in clinical development.
We will evaluate interest from third parties in the compound and its target for other neurobehavioral indications where the target may be relevant, such as schizophrenia.